BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT01248247 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

334

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: AZD6244
DRUG: MK-2206
DRUG: Sorafenib
DRUG: Erlotinib
DRUG: MK-2206

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]